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Background & aims: Teduglutide, promotes intestinal growth and is approved for the treatment of short
bowel syndrome and intestinal failure (SBS-IF) [GATTEX® (teduglutide). Full prescribing information.
Shire-NPS Pharmaceuticals, Inc., Lexington, MA, USA, 2019; Revestive® (teduglutide). Full prescribing
information. Shire Pharmaceuticals Ireland Limited, Dublin, Ireland, 2019.]. Based on the pharmacologic
activity and preclinical ﬁndings, teduglutide can potentially induce proliferative colonic mucosal
changes. The aim of this study is to report the occurrence of colorectal polyps in adult patients with SBS-
IF who received teduglutide in clinical studies conducted to-date.
Methods: A post hoc analysis of the completed Study of Teduglutide Effectiveness in Parenteral
Nutrition-Dependent Short Bowel Syndrome Subjects (STEPS) clinical study series (NCT00798967,
EudraCT 2008-006193-15; NCT00930644, EudraCT 2009-011679-65; NCT01560403) evaluated electronic
case report form data for baseline colonoscopies (performed before treatment) and for surveillance or
end-of-study (performed after treatment with teduglutide 0.05 mg/kg/day for 24 and 36 months) post-
exposure procedures.
Results: In the STEPS studies, 73 patients treated with teduglutide had a baseline colonoscopy. No post-
exposure colonoscopy was scheduled in STEPS. In STEPS-2/3, 50 of 65 patients with remnant colon (77%)
underwent a protocol-mandated post-exposure colonoscopy. Colon polyps were reported at baseline in
12% (9/73) of patients and post-exposure in 18% (9/50) of patients. Two had polyps both at baseline and
post-exposure. On histology, available for seven patients, 5 had adenomas (1 serrated, 4 tubular) and
none had malignancy or high-grade dysplasia.
Conclusion: These data support recommendations for colonoscopic screening before teduglutide therapy
and subsequent on-therapy colonoscopic surveillance for patients with SBS-IF. Further studies are
required to assess the risk of polyp formation in patients with SBS-IF and the most appropriate colon
polyp surveillance strategies.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
107
108
109NA, not applicable; NR, not reported; PBO, placebo; SBS, short bowel syndrome; SBS-IF, short bowel syndrome and
eness in parenteral nutrition-dependent short bowel syndrome subjects; TED, teduglutide.
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Teduglutide, an analog of glucagon-like peptide 2, is
approved for the treatment of patients with short bowel syn-
drome (SBS) dependent on parenteral support [1,2]. Based on
pharmacologic activity and preclinical ﬁndings of this trophic
hormone, the potential for hyperplastic changes was taken into
consideration by regulatory agencies at the time of indication
approval [1,2]. Consequently, the prescribing information and
product monographs propose close colonoscopic surveillance.
Namely, patients should have a colonoscopy with removal of
polyps before the initiation of treatment with teduglutide and
follow-up colonoscopies during treatment [1,2]. However, there
are limited data on the development or progression of polyps in
patients receiving teduglutide. The present study is not powered
to challenge current surveillance recommendations, but this
brief communication does provide additional, albeit limited post
hoc, data regarding the baseline prevalence and incidence of
potentially malignant or pre-malignant lesions in patients tak-
ing teduglutide. The data are derived from the three completed
adult studies in the STEPS clinical trial series [3e5] for all pa-
tients who underwent colonoscopy and had polyps at baseline
or during subcutaneous administration of teduglutide 0.05 mg/
kg/day.90
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1302. Material and methods
This post hoc analysis included all individual colonoscopy data
from the double-blind, placebo-controlled STEPS (NCT00798967;
EudraCT 2008-006193-15) study [3] and its two open-label
extension studies; STEPS-2 (NCT00930644; EudraCT 2009-
011679-65) [4], and STEPS-3 (NCT01560403) [5]. The ﬂow of pa-
tients across the STEPS clinical trial series has been published in
Seidner et al. [5] Patients eligible to participate in STEPS had short
bowel syndrome and intestinal failure (SBS-IF), were parenteral
support dependent for 12 months, and required parenteral sup-
port 3 times weekly. Patients in STEPS-2 had to have completed
24 weeks of treatment (teduglutide or placebo) in STEPS [4] and
patients in STEPS-3 had to have completed 24 months of teduglu-
tide in STEPS-2 [5]. All patients in this post hoc analysis received
teduglutide. All patients had providedwritten informed consent for
study participation. All studies were conducted in accordance with
the Declaration of Helsinki and International Conference on Har-
monisation and Good Clinical Practice, and were approved by local
institutional review boards/independent ethics committees/
research ethics boards.
The study protocol required a baseline colonoscopy for all pa-
tients with colon-in-continuity except those who had a normal
colonoscopy within six months of their screening visit. The colo-
noscopy was performed at the end of the parenteral support sta-
bilization period (baseline study visit) and before randomization to
rule out malignant and high-grade dysplastic lesions. All benign
gastrointestinal polyps had to be removed before randomization
for patients to be eligible for enrollment. An end-of-study colo-
noscopy was required for all enrolled patients at ﬁnal study visit in
STEPS-2 (Month 24) and STEPS-3 (Month 36) or at the early
termination visit for the extension studies. The study protocol did
not preclude surveillance colonoscopies, if needed; collectively
these post-baseline procedures are referred to as post-exposure
colonoscopies. Information regarding polyps was collected via pa-
tient electronic case report forms; a histology report for any
resected lesions was not required. Because the nature of this
analysis was to report individual colonoscopy data, only descriptive
statistics are provided.Please cite this article as: Armstrong D et al., Colon polyps in patients with
of the STEPS study series, Clinical Nutrition, https://doi.org/10.1016/j.clnu3. Results
In the STEPS studies, 73 patients (mean [SD] age 49.8 [14.14]
years; women 57.5%) had a remnant colon and received a pre-
randomization baseline colonoscopy (Supplementary Table 1). No
post-exposure protocol colonoscopy was scheduled in the STEPS
study. In the STEPS-2 and STEPS-3 populations, of the 65 patients
who had a colon 50 patients (77%; mean age 51.5 [13.31] years;
women 56.0%) had a protocol-mandated post-exposure colonos-
copy. A summary of the colonoscopy visits and results for each
individual STEPS study can be found in Supplementary Tables 1e3.
Polyps were reported in nine of 73 patients who underwent the
baseline colonoscopy (Table 1). Five of the nine patients had one
polyp each and the remaining four patients had two or more
polyps. In these patients, the duration of parenteral support, an
indirect measure of SBS-IF disease duration, ranged from one to
24 years.
Table 2 provides the detailed data for the colon polyps reported
in nine (mean age 49.6 [8.80] years; women 77.8%; 193.7 [52.24]
per 100 patient-years) of 50 patients who underwent post-
exposure colonoscopy. In these nine patients, polyps were detec-
ted in three patients who had polyps removed at the baseline co-
lonoscopy (n ¼ 2) or during the 24-month STEPS-2 colonoscopy
(n ¼ 1). The polyps in these three patients were located in colon/
rectum (baseline) and transverse colon/ascending colon/cecum
(post-exposure) in patient No. 6, in rectum (baseline) and colorectal
(post-exposure) in patient No. 8, and colon (STEPS-2) and colon
(post-exposure) in patient No. 10. The duration of teduglutide
exposure at the time of polyp discovery in the nine patients ranged
from eight to 36 months. Histological analyses in seven patients
reported no evidence of malignancy or high-grade dysplasia;
various adenomas were reported in 5 patients (Table 2).
A duodenal polyp (no histology available), detected at gastros-
copy in a 64-year-old man, is not included in the analysis; this
patient had a history of smoking/asbestos exposure and was being
investigated for a non-small cell lung cancer (STEPS-2; the duration
of teduglutide exposure at polyp detection was 3 months following
completion in STEPS where placebo was received).4. Discussion
In average risk adults (ie, no history of adenomatous polyps or
colorectal cancer), the American Cancer Society recommends
screening as early as 45 years of age [6]. An analysis of 9100 colo-
noscopies from a population-based US registry cohort (mean age,
60 years), comprising 68% screening and 32% surveillance colo-
noscopies reported adenoma rates of 25% and 37%, respectively [7].
In patients who had no polyp detected at a baseline screening co-
lonoscopy but had a second surveillance colonoscopy within 5.5
years the rate of adenoma was 16e41% [8].
In the STEPS clinical trial series, polyps were detected during the
screening baseline colonoscopy in 12% (9/73) of patients with SBS-
IF, aged 39e75 years. Among the patients who received long-term
teduglutide and had post-exposure colonoscopies, polyps were
detected in 18% (9/50) of patients. This 24- and 36-month colo-
noscopy data could be considered a short-term second protocol-
driven, not risk-driven, ‘surveillance’ colonoscopy. Collectively in
this post hoc analysis, the reported polyp detection rate for a SBS-IF
population is at the low range of the rates reported in the literature
for the general population [7,8]. Variations in patient demographics
and baseline characteristics may account for the observed differ-
ences in rates of polyp detection. No histological information is
available for the nine patients who had polyps before receiving any
study treatment. Of the seven histology analyses performed inshort bowel syndrome before and after teduglutide: Post hoc analysis
.2019.08.020
Table 1
Characteristics of patients with polyps reported at pre-randomization baseline colonoscopy.a
Patient
number
Sex Age at
screening,
years
Duration of parenteral
support at screening,
years
Etiology of SBS Estimated percent of
colon remaining
Polyp size Location (number of polyps)
1 F 58 1.8 Vascular disease (embolism of
superior mesenteric artery)
60 Not reported Colon (1)
2 F 45 1.9 Vascular disease (venous
mesenteric infarction)
70 Not reported Colon (1)
3 M 46 5.9 Vascular disease (mesenteric
infarction)
90 Not reported Colon (1)
4 M 68 7.0 Vascular disease (embolism of
mesenteric artery)
100 Not reported Colon and rectum (multiple)
5 F 75 5.8 Vascular disease (occlusion of
superior mesenteric artery)
50 5 mm Rectum (1)
6b F 47 1.0 Vascular disease (thrombosis of
mesenteric artery)
100 4 mm Colon (1)
1e2 mm Rectum (multiple)
7 M 39 1.7 Other (volvulus) 30 Not reported Large intestine (multiple)
8b F 49 24.7 Other (injury) 100 Not reported Rectum (2)
9 F 43 1.1 Other (small bowel infarction) 100 Not reported Not reported (1)
F, female; M, male; SBS, short bowel syndrome.
a No histopathology data are available.
b Patient also had polyps reported at a post-exposure colonoscopy.
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YCLNU3996_proof ■ 30 August 2019 ■ 3/4patients who received long-term teduglutide, there was no evi-
dence of malignancy or high-grade dysplasia.
This post hoc analysis has some limitations. Although this
analysis used all available colonoscopy data collected, the STEPSTable 2
Characteristics of patients with polyps reported at post-exposure colonoscopy.
Patient
number
Sex/age at
screening,
years
Duration of
parenteral
support at
screening,
years
Etiology of SBS Estimated
percent of
colon
remaining
Treatment
group, STEPS/
STEPS-2/STEPS-
3
Po
de
ba
col
6d F/47 1.0 Vascular
disease
(thrombosis of
mesenteric
artery)
100 PBO/TED/NA Ye
8d F/49 24.7 Other (injury) 100 TED/TED/NA Ye
10 F/46 24.0 IBD (Crohn's
disease)
25 PBO/TED/TED No
11 M/62 3.0 Vascular
disease
(ischemic
event)
50 PBO/TED/NA No
12e F/55 9.6f Vascular
disease
(unknown)
50 TED/TED/NA No
13 F/41 1.9f Other (injury) 75 PBO/TED/TED No
14 F/61 1.2g Other
(strangulated
intestine)
50 TED/TED/TED No
15 F/35 4.2 Other
(volvulus)
Not
reported
PBO/TED/NA No
16 M/50 4.1 Other (jejunal
ﬁstula)
50 PBO/TED/NA No
F, female; IBD, inﬂammatory bowel disease; M, male; NA, not applicable; NR, not report
a Exposure includes time in STEPS study, mean (SD) is 193.7 (52.24) per 100 patient-y
b Histology analyses in all except patients 5 and 9.
c Polyp detected during 24-month STEPS-2 colonoscopy was removed before patient
d Patient also had polyps reported at a pre-randomization baseline colonoscopy.
e Non-study colonoscopy performed as part of workup for diverticulitis.
f PS-independent by the end of study (all during STEPS-2).
g Tubular adenoma reported as colonoscopy ﬁnding.
h Early termination colonoscopy (Day 57).
Please cite this article as: Armstrong D et al., Colon polyps in patients with
of the STEPS study series, Clinical Nutrition, https://doi.org/10.1016/j.clnustudy program was not designed to investigate polyp formation in
detail. Particularly, the study design permitted a comparison be-
tween teduglutide and placebo for the ﬁrst 24 weeks; thereafter, all
patients received teduglutide for up to two years. Furthermore, thelyp
tected at
seline
onoscopy
Duration of TED
exposure at
time of polyp
detection,
monthsa
Location
(number of
Polyps)
Size, cm Histopathologyb
s 24 Transverse
colon (2)
0.3e0.7 Probable whole serrated
adenomas
Ascending
colon (2)
NR
Cecum (1) NR
s 8h Colorectal
(3)
NR Tubular adenoma with low-
grade dysplasia, and
tubulo-villous adenoma
(rectum)
c 24 Colon (3) 0.2e0.5 Hyperplastic polyp
36 Colon (NR) NR NR
24 Colon (2) 0.3e0.5 Tubular adenomas
10 Rectum
(1)
NR Inﬂamed polyp lesion, no
neoplasm, acute proctitis
with surface necrosis, acute
inﬂammation, and
prominent crypt epithelial
regeneration
36 Colon (1) NR Not resectedg
29 Cecum (2) NR Tubular adenomas
24 Rectum
(1)
0.2 Tubular adenoma with low-
grade dysplasia
24 Not
speciﬁed
NR Not resected
ed; PBO, placebo; SBS, short bowel syndrome; TED, teduglutide.
ears.
continued in STEPS-3.
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YCLNU3996_proof ■ 30 August 2019 ■ 4/4protocol was not designed to capture baseline polyp characteristics,
risk factors for the development of polyps or colorectal cancer, or
prior colonoscopies in patients >50 years of age. The conclusions
are, therefore, constrained by the small population size, the
descriptive nature of the ﬁndings, and the limited data-reporting
requirements for the colonoscopy and histology. It is possible that
polyps identiﬁed during the follow-up colonoscopy did not develop
de novo between procedures, but rather were undetected during
the baseline colonoscopy. We did not include data from other
clinical studies, noted in some regional prescribing information
documents [1], that used higher doses than the approved 0.05/mg/
day teduglutide (2 cases) or included intestinal polyps (2 cases).
Overall, these colonoscopy results support the recommendation
in the teduglutide prescribing information regarding colonoscopic
surveillance [1,2]. A polyp detection rate of 12% supports baseline
colonoscopy before starting teduglutide. Moreover, careful
screening at the baseline is critical to detect cancers that would
otherwise preclude teduglutide therapy and for the detection and
removal of polyps that might be at risk of progression during
treatment. This would also minimize the risk of undetected polyps,
which, if detected at the recommended 1e2 year colonoscopy,
would necessitate earlier or more frequent surveillance. Most pa-
tients (>70% with no polyps at baseline or follow up colonoscopy)
could then be monitored every 5 years thereafter. An ongoing
global, observational SBS registry (NCT01990040; EUPAS7973) is
designed to providemore detailed information on the development
of colon polyps in patients with SBS-IF and may lead to revision of
the current regulatory guidance on surveillance colonoscopy.
Newer mechanical endoscopic devices such as magnifying chro-
moendoscopy and magnifying narrow-band imaging have mark-
edly improved detection of adenomas and polyps [9]. It is possible
that these novel diagnostics along with histological, molecular, and
stool-based techniques may be adopted, after appropriate valida-
tion, for screening and surveillance of patients treated with
teduglutide.
5. Conclusion
These data provide some additional information about the risk
of polyp formation in patients with SBS-IF and in patients treated
with teduglutide. They support the recommendations for a base-
line, pre-treatment colonoscopy and subsequent surveillance
colonoscopies in the teduglutide regulatory prescribing labels
which should be considered in conjunction with local guidelines
and policies for colorectal cancer screening in average risk and high
risk individuals.
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